Clinical trials›Glaucoma›Device›Trial details
OpenAvailable NowTreatment Study

Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma

For Condition: Glaucoma

ID: NCT07209410

Horizon Patient Guidance Summary

Our intelligence engine has synthesized this trial record to answer your most important questions in clear, simple terms:

How it’s taken
Digital Tech & Devices
Expected Availability Horizon
Available Now (Approved)
StageApproved Treatment: Already FDA approved and actively prescribed in clinics. This study collects post-market real-world safety metrics.
EligibleHealthy volunteers welcome — you do not need to be diagnosed with the condition to participate.
About This Clinical Trial

To evaluate the effect of brimonidine tartrate 0.025% on conjunctival hyperemia in patients treated with netarsudil 0.02%/latanoprost 0.005% mono-therapy for intraocular pressure lowering.

Study Timeline & Quick Facts
Trial Status
Open — Looking for Participants
Total Target Enrollment
35 patients (Estimated)
Study Start Date
2025-11-01
Est. Primary Completion
2026-12-15
Tested Drugs & Treatment Groups
DRUGBrimonidine Tartrate Ophthalmic 0.025%

Lumify is an approved eye drop to minimize ocular hyperemia.

Treatment Arms Description

EXPERIMENTALBrimonidine Tartrate

Patients experiencing hyperemia greater than grade 2 on Efron scale will receive brimonidine tartrate (Lumify). Photo documentation of hyperemia and patient satisfaction questionnaires will be administered.

Can I Join This Study?
Suitable For
Everyone welcome
Ages Welcome
Between 18 Years and 65 Years
Full Criteria Checklist
Who Can Join
  • 1\. Adult patients 18-65 years old diagnosed with open-angle glaucoma or ocular hypertension.
  • 2\. Currently on netarsudil 0.02%/latanoprost 0.005% monotherapy for a minimum of 2-6 weeks.
  • 3\. Able to move from current topical glaucoma treatment to netarsudil 0.02%/latanoprost 0.005% for a minimum of 4 weeks or longer based on FDA recommended washout per drug classification prior to Visit 3.
  • 4\. Experience conjunctival redness as graded on the Efron scale of at least grade 2 after minimum of 4 weeks on netarsudil 0.02%/latanoprost 0.005% mono-therapy or longer based on recommended washout per drug classification 4. Have a best corrected Visual Acuity by Snellen chart of 20/30 or better in study eye.
  • 5\. Are willing and able to self-administer or have an able person available to assist with administration of study drug.
  • Willing and able to comply with study procedures and attend follow-up visits.
Who Cannot Join
  • Allergy or hypersensitivity to brimonidine or other components of brimonidine tartrate 0.025% or netarsudil 0.02%/latanoprost 0.005%.
  • Use of any other topical ocular medications.
  • Active ocular infection, inflammation unrelated to glaucoma therapy, uveitis, iritis or congenital aphakia.
  • Have pterygium/pinguecula, chemosis, episcleritis, scleritis (or any condition that may affect hyperemia grading) in the opinion of the investigator
  • Have moderate or severe dry eyes.
  • Pregnant, plan to become pregnant or breastfeeding.
  • Concurrent or past use in the last 90 days of vasoconstrictive ocular drops other than brimondine 0.025%
  • Have undergone previous incision IOP lowering surgeries.
  • Have undergone previous laser surgery for glaucoma (selective laser trabeculoplasty (SLT) or argon laser trabeculoplasty (ALT)), or microinvasive glaucoma surgery (MIGS) with 6 months of screening.
  • Have had intraocular or per-ocular surgery within the past 3 months.
  • Advanced glaucoma or c/d ratio greater than 0.8. Are non-responsive to topical treatment with netarsudil 0.02%/latanoprost 0.005%.
  • In the judgement of the investigator, have previous or currently active clinically significant systemic or ocular disease in either eye that could affect study outcomes.
What is this Study Measuring?

Primary Outcome Measures

  • Effron Grading scale of ocular redness — Time Frame: 2 weeks

    Measuring Ocular Hyperemia and injection. This is measured on Scale 0-4 0- Normal 1. Trace 2. Mild 3. Moderate 4. Severe

Where to Participate

This trial is recruiting at 1 study facilities worldwide. Click below to see if there is a clinic or hospital in your area:

Show All 1 Facilities & Contact Sites
Vision Source
Kansas City, Missouri, United States
Status: Open
Trial Design & Scientific Setup
Allocation
na
Intervention Model
single group
Primary Purpose
treatment
Masking
none
Sponsoring Teams & Contacts
Lead Sponsoring Institution
Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,
Primary Research Contact
Crystal Remington Optometrist, OD
Tel: 816-531-9100
Clinical Trial Application Copilot

Want to apply or inquire about joining this study? Fill out this simple questionnaire, and our assistant will instantly generate a professional email draft you can copy and send to the central contact coordinator listed above!

Generated Professional Email Draft:
View Official Medical/Scientific Title

Impact of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma

Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma — NCT07209410